Migyeong Jo

Title: The Innovative Contributions of Migyeong Jo

Introduction

Migyeong Jo is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of novel therapeutic agents. With a total of three patents to his name, his work focuses on enhancing the efficacy of treatments for various diseases, including cancer.

Latest Patents

One of Migyeong Jo's latest patents is centered around an aglycosylated antibody Fc region for treating cancer. This invention involves a polypeptide that contains an Fc domain, where part of the amino acid sequence of a human antibody Fc domain is substituted with another sequence. This optimization allows for superior selective binding ability to FcγRIIIa among Fc receptors, making it a promising candidate for cancer treatment. Additionally, he has developed Fc-gamma receptor mutants, which are polypeptides optimized for excellent selective binding to immunoglobulins. These mutants can enhance the in vivo half-life of drugs and are useful in various applications, including organ transplant rejection prevention and autoimmune disease treatment.

Career Highlights

Migyeong Jo has worked at Kookmin University and the Kookmin University Industry Academy Cooperation Foundation. His roles in these institutions have allowed him to collaborate with other researchers and contribute to advancements in medical science.

Collaborations

Some of his notable coworkers include Sang Taek Jung and Sanghwan Ko. Their collaborative efforts have furthered the research and development of innovative solutions in the field.

Conclusion

Migyeong Jo's work exemplifies the impact of innovative thinking in biotechnology. His patents not only advance scientific knowledge but also hold the potential to improve patient outcomes in cancer treatment and other medical applications.